Patents by Inventor Sylvia Miescher

Sylvia Miescher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment and prevention of remote ischemia-reperfusion injury
    Patent number: 10973891
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 13, 2021
    Assignees: CSL Behring GmbH, Universitaet Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
    Publication number: 20190269766
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Inventors: Rolf SPIRIG, Sylvia MIESCHER, Marc NOLTE, Claudia DUEHRKOP-SISEWITSCH, Robert RIEBEN
  • Treatment and prevention of remote ischemia-reperfusion injury
    Patent number: 10286047
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 14, 2019
    Assignees: CSL Behring GmbH, Universität Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Compositions comprising secretory-like immunoglobulins
    Patent number: 10221233
    Abstract: The invention relates to methods for preparing compositions comprising secretory-like immunoglobulin, in particular secretory-like IgA and/or secretory-like IgM, and compositions obtainable by the methods.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: March 5, 2019
    Assignee: CSL BEHRING AG
    Inventors: Blaise Corthésy, Stéphanie Longet, Marius Loetscher, Sylvia Miescher, Adrian Zuercher
  • Prevention of infection
    Patent number: 9932392
    Abstract: The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 3, 2018
    Assignees: CSL BEHRING AG, BETH ISRAEL DEACONESS MEDICAL CENTER INC
    Inventors: Ciaran Kelly, Xinhua Chen, Sylvia Miescher, Martin Spycher, Sandra Wymann, Adrian Zuercher
  • CD89 ACTIVATION IN THERAPY
    Publication number: 20170166640
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 15, 2017
    Applicants: CSL BEHRING AG, UNIVERSITÄT BERN
    Inventors: Stephan VON GUNTEN, Marc WEHRLI, Adrian ZÜRCHER, Sylvia MIESCHER
  • Treatment of mucositis with immunoglobulin
    Patent number: 9546209
    Abstract: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: January 17, 2017
    Assignees: CSL Behring AG, Universitaet Bern
    Inventors: Christoph Aebi, Sonja Christina Lueer, Alexander Schaub, Sylvia Miescher, Adrian Zuercher, Cédric Pierre Vonarburg
  • CD89 activation in therapy
    Patent number: 9522184
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 20, 2016
    Assignees: CSL BEHRING AG, UNIVERSITAT BERN
    Inventors: Stephan Von Gunten, Marc Wehrli, Adrian Zürcher, Sylvia Miescher
  • TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
    Publication number: 20160008442
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitor to an individual.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 14, 2016
    Inventors: Rolf SPIRIG, Sylvia MIESCHER, Marc NOLTE, Claudia DUEHRKOP-SISEWITSCH, Robert RIEBEN
  • COMPOSITIONS COMPRISING SECRETORY - LIKE IMUNOGLOBULINS
    Publication number: 20150056180
    Abstract: The invention relates to methods for preparing compositions comprising secretory-like immunoglobulin, in particular secretory-like IgA and/or secretory-like IgM, and compositions obtainable by the methods.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 26, 2015
    Inventors: Blaise Corthésy, Stéphanie Longet, Marius Lötscher, Sylvia Miescher, Adrian Zürcher
  • TREATMENT OF MUCOSITIS WITH IMMUNOGLOBULIN
    Publication number: 20150030613
    Abstract: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 29, 2015
    Inventors: Christoph Aebi, Sonja Christina Lueer, Alexander Schaub, Sylvia Miescher, Adrian Zürcher, Cédric Pierre Vonarburg
  • PREVENTION OF INFECTION
    Publication number: 20150017181
    Abstract: The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 15, 2015
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER INC, CSL BEHRING AG
    Inventors: Ciaran Kelly, Xinhua Chen, Sylvia Miescher, Martin Spycher, Sandra Wymann, Adrian Zuercher
  • Antibody composition with altered Fab sialylation
    Patent number: 8632773
    Abstract: The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 21, 2014
    Assignees: CSL Behring AG, University of Washington
    Inventors: Fabian Käsermann, Monika Rüegsegger, Sylvia Miescher, Keith Elkon
  • CD89 ACTIVATION IN THERAPY
    Publication number: 20130302345
    Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
    Type: Application
    Filed: December 14, 2011
    Publication date: November 14, 2013
    Applicants: UNIVERSITÄT BERN, CSL BEHRING AG
    Inventors: Stephan Von Gunten, Marc Wehrli, Adrian Zürcher, Sylvia Miescher
  • ANTIBODY COMPOSITION OBTAINED BY FRACTIONATION OF PLASMA IMMUNOGLOBULINS AFFINITY CHROMATOGRAPHY ON A SAMBUCUS NIGRA AFFINITY COLUMN
    Publication number: 20130058917
    Abstract: The invention relates to populations of antibodies obtainable by fractionation of plasma immunoglobulins, in particular plasma IgG, by affinity chromatography on a Sambucus nigra affinity column, and uses thereof.
    Type: Application
    Filed: May 4, 2011
    Publication date: March 7, 2013
    Inventors: Fabian Käsermann, Sylvia Miescher
  • ANTIBODY COMPOSITION WITH ALTERED FAB SIALYLATION
    Publication number: 20120009189
    Abstract: The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 12, 2012
    Inventors: Fabian Käsermann, Monika Rüegsegger, Sylvia Miescher, Keith Elkon
  • Immunoglobulin fractions
    Patent number: 7887797
    Abstract: The present invention relates to novel pharmaceutical compositions comprising fractions of human immunoglobulin preparations, novel applications of these compositions and a method for manufacturing the compositions.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: February 15, 2011
    Assignee: CSL Behring AG
    Inventors: Sylvia Miescher, Reinhard Franz Bolli
  • Immunoglobulin fractions
    Publication number: 20090028846
    Abstract: The present invention relates to novel pharmaceutical compositions comprising fractions of human immunoglobulin preparations, novel applications of these compositions and a method for manufacturing the compositions.
    Type: Application
    Filed: October 27, 2005
    Publication date: January 29, 2009
    Inventors: Sylvia Miescher, Reinhard Franz Bolli
  • Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
    Patent number: 7429647
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: September 30, 2008
    Inventors: Andreas Morell, Martin Imboden, Beda Statler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
  • Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
    Patent number: 7399471
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: July 15, 2008
    Assignee: ZLB Behring AG
    Inventors: Andreas Morell, Martin Imboden, Beda Stadler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz